Skip to main content

Table 1 Treatments received by newly-referred adult CFS/ME patients across CFS/ME specialist services

From: Specialist treatment of chronic fatigue syndrome/ME: a cohort study among adult patients in England

Service   Median (IQR) total number of sessions Median (IQR) total session time (hours) Median (IQR) total individual face-to-face session time (hours)a Median (IQR) total group session time (hours)a
A Treatment data available, N = 126 4 (2–8), mean 5.6 6 (3–13), mean 8.2 2 (1–4), mean 3.1 4 (4–12), mean 8.0
  With follow-up data (64/126 (50.8%)) 5 (2–8), mean 5.4 6 (4–13), mean 7.9 2 (1–4), mean 3.1 4 (4–12), mean 7.8
  Discharged before follow-up (41/64 (64.1%)) 3 (1–5), mean 3.7 5 (1–9), mean 5.8 1 (1–2), mean 2.0 4 (4–12), mean 7.2
B Treatment data available, N = 55 6 (2–10), mean 7.1 6 (2–13), mean 9.5 6 (4–7), mean 6.2 18 (7–24), mean 16.8
  With follow-up data (23/55 (41.8%)) 7 (3–12), mean 8.2 7 (3–15), mean 10.7 7 (5–8), mean 7.2 18 (18–28), mean 19.7
  Discharged before follow-up (5/23 (21.7%)) 5 (4–5), mean 5.0 5 (4–5), mean 5.0 5 (4–5), mean 5.0 -
C Treatment data available, N = 22b 11 (9–12), mean 10.0 19 (17–21), mean 18.4 1 (1–2), mean 1.7 18 (16–20), mean 16.8
  Discharged before follow-up (7/22 (31.8%)) 9 (7–11), mean 9.0 17 (13–21), mean 17.0 1 (1–1), mean 1.8 16 (10–20), mean 15.1
D Treatment data available, N = 42 5 (2–8), mean 5.1 4 (3–6), mean 4.7 3 (2–6), mean 4.2 -
  With follow-up data (25/42 (59.5%)) 7 (4–8), mean 6.3 6 (4–7), mean 5.7 5 (3–7), mean 5.1 -
  Discharged before follow-up (13/25 (52.0%)) 7 (3–8), mean 6.2 5 (4–7), mean 5.6 4 (3–6), mean 4.8 -
E Treatment data available, N = 133 6 (4–7), mean 5.6 6 (4–7), mean 5.9 6 (3–7), mean 5.4 11 (6–12), mean 9.7
  With follow-up data (83/133 (62.4%)) 6 (4–7), mean 5.9 6 (4–7), mean 6.1 6 (4–7), mean 5.8 11 (11–11), mean 11.1
  Discharged before follow-up (26/83 (31.3%)) 7 (4–7), mean 5.8 7 (4–8), mean 6.2 6 (3–7), mean 5.5 11 (11–14), mean 11.5
F Treatment data available, N = 78 13 (9–14), mean 11.7 15 (10–18), mean 13.9 6 (5–11), mean 7.4 6 (1–13), mean 6.6
  With follow-up data (58/78 (74.4%)) 13 (11–15), mean 12.7 17 (13–18), mean 15.2 7 (5–12), mean 8.3 8 (1–13), mean 7.2
  Discharged before follow-up (27/58 (46.6%)) 12 (6–13), mean 10.3 16 (7–18), mean 12.9 5 (5–9), mean 5.8 10 (1–13), mean 7.7
G Treatment data available, N = 25 12 (8–21), mean 13.0 12 (7–22), mean 13.8 12 (7–17), mean 13.2 8 (1–15), mean 7.5
  With follow-up data (7/25 (28.0%)) 11 (8–25), mean 14.4 10 (8–31), mean 16.3 10 (8–17), mean 14.2 15 (n = 1)
  Discharged before follow-up (4/7 (57.1%)) 11 (8–18), mean 12.8 10 (7–21), mean 14.0 10 (7–13), mean 10.4 15 (n = 1)
H Treatment data available, N = 133 5 (1–9), mean 5.7 No data No data No data
  With follow-up data (60/133 (45.1%)) 6 (2–11), mean 6.8 No data No data No data
  Discharged before follow-up (19/60 (31.7%)) 6 (5–9), mean 7.0 No data No data No data
I Treatment data available, N = 50 7 (2–10), mean 6.3 9 (3–15), mean 9.1 1 (0.3–6), mean 3.0 14 (8–16), mean 12.2
  With follow-up data (26/50 (52.0%)) 9 (5–11), mean 7.9 13 (7–16), mean 11.8 0.3 (0.3–4), mean 2.6 14 (10–17), mean 13.6
  Discharged before follow-up (4/26 (15.4%)) 5 (1–7), mean 4.0 5 (1–7), mean 4.0 7 (2–7), mean 5.3 -
J Treatment data available, N = 47# 5 (3–11), mean 6.4 4 (3–14), mean 8.7 2 (2–3), mean 2.8 2 (2–2), mean 7.0
  Discharged before follow-up (23/47 (31.8%)) 3 (2–4), mean 3.2 3 (2–4), mean 2.9 2 (1–3), mean 1.9 2 (2–2), mean 1.4
K Treatment data available, N = 31 12 (10–13), mean 11.8 20 (16–23), mean 18.2 3 (2–5), mean 3.8 18 (14–20), mean 17.0
  With follow-up data (20/31 (64.5%)) 12 (10–15), mean 12.9 20 (17–24), mean 19.1 3 (2–6), mean 3.7 17 (16–20), mean 17.1
  Discharged before follow-up (9/20 (45.0%)) 12 (9–13), mean 10.4 18 (17–23), mean 17.7 2 (2–3), mean 2.5 16 (15–21), mean 17.2
  1. a Excluding patients who did not have any sessions of this type
  2. bTreatment data were only extracted for patients who had 1-year follow-up data